Vigil Neuroscience, Inc., (VIGL): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
VIGL Stock Price Chart Interactive Chart >
VIGL Price/Volume Stats
|Current price||$2.83||52-week high||$18.27|
|Prev. close||$2.78||52-week low||$2.18|
|Day high||$3.12||Avg. volume||91,295|
|50-day MA||$3.34||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||80.00M|
Vigil Neuroscience, Inc., (VIGL) Company Bio
Vigil Neuroscience, Inc., a biotechnology company, discovers and develops novel therapeutics that take advantage of breakthroughs in science and human genetics of microglia. It harnesses the power of microglia for the treatment of neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.
Most Popular Stories View All
VIGL Latest News Stream
|Loading, please wait...|
VIGL Latest Social Stream
View Full VIGL Social Stream
Latest VIGL News From Around the Web
Below are the latest news stories about Vigil Neuroscience Inc that investors may wish to consider to help them evaluate VIGL as an investment opportunity.
In terms of doing mergers and acquisitions and raising money through initial public offerings, 2021 was huge. But 2022 may be vastly different.
Whether you're new to the stock market or have been investing for years, initial public offerings (IPOs) can be exciting. An IPO happens when a company begins offering shares of stock for the first time. Could any of these three IPOs be a good fit for your portfolio?
Amylyx Pharmaceuticals, Vigil Neurosciences and CinCor Pharma all gained ground Tuesday after falling below their IPO prices on Monday.
CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the closing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $14.00 per share. The gross proceeds of the offering were $98 million, before deducting underwriting discounts and commissions and other offering
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares are being offered by Vigil Neuroscience. The gross proceeds of the offering, before deducting underwriting di
VIGL Price Returns